Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden

• Published in: BMJ open 2023-11, Vol.13 (11), p.e076900-e076900
• Main Authors: Lindahl, Jesper, Asp, Marie, Ståhl, Darya, Tjernberg, Johanna, Eklund, Moa, Björkstrand, Johannes, van Westen, Danielle, Jensen, Jimmy, Månsson, Kristoffer, Tornberg, Åsa, Svensson, Martina, Deierborg, Tomas, Ventorp, Filip, Lindqvist, Daniel
• Format: Article
• Language: English
• Subjects: adult psychiatry; Anhedonia; Antidepressants; Biomarkers; Bipolar disorder; Clinical Medicine; depression & mood disorders; Depression - drug therapy; Diagnostic tests; Dopamine; Drug dosages; Electroconvulsive therapy; Follow-Up Studies; Humans; Inflammation; Ketamine; Klinisk medicin; Medical and Health Sciences; Medicin och hälsovetenskap; Mental depression; Mental health; Pathophysiology; Patients; Pramipexole - therapeutic use; Psychiatry; Psykiatri; Quality of life; randomized controlled trial; Randomized Controlled Trials as Topic; Remission (Medicine); Sweden; Treatment resistance
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2023-076900

IntroductionMany depressed patients do not achieve remission with available treatments. Anhedonia is a common residual symptom associated with treatment resistance as well as low function and quality of life. There are currently no specific and effective treatments for anhedonia. Some trials have shown that dopamine agonist pramipexole is efficacious for treating depression, but more data is needed before it could become ready for clinical prime time. Given its mechanism of action, pramipexole might be a useful treatment for a depression subtype characterised by significant anhedonia and lack of motivation—symptoms associated with dopaminergic hypofunction. We recently showed, in an open-label pilot study, that add-on pramipexole is a feasible treatment for depression with significant anhedonia, and that pramipexole increases reward-related activity in the ventral striatum. We will now confirm or refute these preliminary results in a randomised controlled trial (RCT) and an open-label follow-up study.Methods and analysisEighty patients with major depression (bipolar or unipolar) or dysthymia and significant anhedonia according to the Snaith Hamilton Pleasure Scale (SHAPS) are randomised to either add-on pramipexole or placebo for 9 weeks. Change in anhedonia symptoms per the SHAPS is the primary outcome, and secondary outcomes include change in core depressive symptoms, apathy, sleep problems, life quality, anxiety and side effects. Accelerometers are used to assess treatment-associated changes in physical activity and sleep patterns. Blood and brain biomarkers are investigated as treatment predictors and to establish target engagement. After the RCT phase, patients continue with open-label treatment in a 6-month follow-up study aiming to assess long-term efficacy and tolerability of pramipexole.Ethics and disseminationThe study has been approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. The study is externally monitored according to Good Clinical Practice guidelines. Results will be disseminated via conference presentations and peer-reviewed publications.Trial registration numberNCT05355337 and NCT05825235.